(AIM: SAR) |
14 October 2014 |
Sareum Holdings plc
(“Sareum” or “the Company”)
Final Results
Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, is pleased to announce its final results for the year ended 30 June 2014.
Operational Highlights
Financial Highlights
Dr Tim Mitchell, Chief Executive Officer of the Company, said:
“We have reached a key phase in two of our development programmes where we are progressing rapidly towards human trials. As we achieve significant milestones the commercial interest in, and value of, our programmes are increasing. The next period will prove to be a pivotal one for the Company. With multiple research programmes in progress, we are giving ourselves every chance of success in commercialising and/or conducting human clinical trials in at least one of them.”
Enquiries:
Sareum Holdings plc |
|
Tim Mitchell |
01223 497 700 |
Sanlam Securities UK Limited (NOMAD) |
|
Simon Clements / James Thomas |
020 7628 2200 |
Hybridan LLP (Broker) |
|
Claire Noyce / William Lynne |
0203 713 4581 / 4582 |
The Communications Portfolio (Media enquiries) |
|
Ariane Comstive |
+44 (0) 20 7536 2028 |
ariane.comstive@communications-portfolio.co.uk |
|
Annual Results 2014 available as PDF document: Annual Results 2014